Form 8-K - Current report:
SEC Accession No. 0001213900-25-045648
Filing Date
2025-05-20
Accepted
2025-05-20 08:00:12
Documents
15
Period of Report
2025-05-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242614-8k_nkgen.htm   iXBRL 8-K 34100
2 COMMON STOCK PURCHASE WARRANT, DATED MAY 14, 2025, BY AND BETWEEN NKGEN BIOTECH, ea024261401ex4-1_nkgen.htm EX-4.1 136293
3 SECURITIES PURCHASE AGREEMENT, DATED MAY 14, 2025, BY AND BETWEEN NKGEN BIOTECH, ea024261401ex10-1_nkgen.htm EX-10.1 174808
  Complete submission text file 0001213900-25-045648.txt   634383

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nkgn-20250514.xsd EX-101.SCH 3881
5 XBRL DEFINITION FILE nkgn-20250514_def.xml EX-101.DEF 26778
6 XBRL LABEL FILE nkgn-20250514_lab.xml EX-101.LAB 37007
7 XBRL PRESENTATION FILE nkgn-20250514_pre.xml EX-101.PRE 25402
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0242614-8k_nkgen_htm.xml XML 5591
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 25966182
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)